About PRONEUROGEN INC
ProNeurogen is a biotechnology company focused on developing first-in-class therapies to preserve cognitive function in vascular dementia by targeting the neurovascular drivers of brain disease. The company is currently developing PNA5, a glycosylated Mas receptor agonist designed to protect brain health.
Development of therapies for vascular dementiaResearch and development of PNA5, a glycosylated Mas receptor agonistNeurovascular unit stabilization and brain inflammation reduction
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to PRONEUROGEN INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.